Company news
PharmaCyte Biotech, Inc. news in 2022
PharmaCyte Biotech, Inc.'s news releases, calls and decks from 2022, newest first.
Submission of Matters to a Vote of Security Holders (form 8-K)
December 30, 2022
Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
November 18, 2022
Change in Directors or Principal Officers (form 8-K)
November 7, 2022
Change in Directors or Principal Officers, Shareholder Director Nominations, Other Events, Financial Statements and Exhibits (form 8-K)
October 14, 2022
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
October 6, 2022
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
August 14, 2022
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
July 27, 2022
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
July 20, 2022
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
July 18, 2022
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
July 10, 2022
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
July 4, 2022
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
June 14, 2022
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
June 12, 2022
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
June 7, 2022
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
June 1, 2022
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
May 22, 2022
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
April 26, 2022
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
April 18, 2022
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
April 12, 2022
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
April 4, 2022
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
March 21, 2022
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
March 15, 2022
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
February 21, 2022
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
February 13, 2022
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
January 5, 2022
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
January 3, 2022
Decks in 2022
- Investor Presentation (March 2022)
Investor deck · 44 slides · Mar 9, 2022